In vivo studies have shown that BBR can inhibit lipogenesis and promote FAO by activating the SIRT3/AMPK/ACC pathway in the liver, thereby improving hepatic steatosis (Zhang et al., 2019a). The gene discussed is PRKAA1; the disease is fatty liver disease.